EyePoint Pharmaceuticals reported that Wet AMD is the leading cause of vision loss in the US.
2 reports, 1 independent
Updated Aug 26
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
EyePoint Pharmaceuticals reported that Wet AMD is the leading cause of vision loss in the US.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- EyePoint Pharmaceuticals developed Duravyu for wet AMD treatment.Sub-event
Wet AMD is identified as the leading cause of vision loss in the US.1 source
Keep exploring
The entities involved
-
EyePoint Pharmaceuticals (United Kingdom)
company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery
Coverage
Newest first; wire copies grouped- GlobeNewswireEyePoint Announces Participation at Upcoming Investor Conferences WATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing
- GlobeNewswireEyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to de